Cohort profile: The Australian Parkinson’s Genetics Study (APGS)

Background

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects 2-3% of the global population over 65 years [1]. At present, over 100,000 Australians have PD, and approximately 32 new cases are diagnosed every day [2]. The economic cost of Parkinson’s disease in Australia was estimated at almost $10 billion per year in 2015, but the prevalence and total financial cost associated with the disease have increased dramatically since then [3]. The number of newly diagnosed PD cases is expected to double over the coming decades due to population ageing, posing substantial challenges to the healthcare system, the economy, and society [4].

The pathological hallmarks of PD include nigrostriatal degeneration and widespread intracellular accumulation of Lewy bodies in multiple brain regions. The aetiological pathways of PD are mostly unknown. A vast range of risk factors have been explored, including certain drugs, head trauma, lifestyle factors, comorbid diseases, and exposure to toxic environmental agents [5–7]. In particular, age, mood disorders, consumption of well water [8], head injury [9], and exposure to environmental toxins [10,11] have been consistently associated with an increased PD risk. On the contrary, smoking and caffeine have been inversely related to PD risk and positively correlated with a later age of onset [12,13], suggesting a putative protective effect that needs further exploration. Associations with alcohol remain controversial [14].

The clinical manifestations of PD are highly heterogeneous. Diagnosis is based on the presence of cardinal motor symptoms, including resting tremor, bradykinesia, muscle rigidity, gait difficulty, and postural instability [1]. Non-motor symptoms are also common, particularly in late-stage PD, and involve cognitive impairment (e.g., executive dysfunction and attentional deficits), psychotic symptoms (e.g., visual hallucinations), autonomic dysfunction (e.g., orthostatic hypotension, urogenital incontinence, and constipation), disorders of sleep and mood, hyposmia, fatigue and chronic pain [15]. Notably, some comorbid medical conditions such as constipation, hyposmia, REM sleep behaviour disorder, diabetes and mood disorders may precede the onset of motor disability by years or even decades and serve as pre-diagnostic PD symptoms [16]. Thus, it is worth noting that PD onset, clinical presentation, and progression differ substantially among patients [17].

PD has a complex genetic architecture, with both monogenic and sporadic forms. A twin study in the Swedish Twin Registry estimated heritability at 34%, with concordance rates for PD of 11% for monozygotic twins and 4% for same-sexed dizygotic twin pairs [18]. Rare coding variants detected in the LRRK2, VPS12C, GBA and SNCA genes are associated with monogenic (familial) PD forms [19], whereas common variants around the same GBA, SNCA and LRRK2 genes have also been associated with sporadic (non-familial) PD [20]. A recent GWAS meta-analysis of 17 cohorts identified 90 independent single-nucleotide polymorphisms (SNPs) across 78 genomic regions associated with sporadic Parkinson’s risk [21]. Despite this remarkable progress, common genetic variants only explain around 22% (95% CI 18% - 26%) of PD risk on the liability scale, implying that there are still many more unidentified genetic variants contributing to PD susceptibility. It has been pointed out that the inclusion of diverse populations in genetic studies improves the utility of genetic discovery [22]. However, until now, genetic studies of PD have focused mainly on European ancestry individuals, limiting their capacity to extrapolate results to other ethnicities. Australia is an ethnically diverse country, but the disease epidemiology among various ethnic groups has not been investigated [23,24].

Treatment response in PD is complex and poorly understood [25]. Although there is currently no cure for PD, a combination of pharmacological (e.g., levodopa, dopamine receptor agonists, anticholinergics) and non-pharmacological (e.g., physiotherapy, deep brain stimulation) therapies are the only available treatment options. However, such interventions only ameliorate the symptoms of the illness, and their long term use is associated with adverse side effects in some patients [26,27], which in turn result in suboptimal medication compliance and low quality of life. Research seeking to identify the disease’s genetic components that contribute to drug response variability could lead to the discovery of personalised disease-modifying therapies with great potential to improve PD patients’ well-being and quality of life.

Few studies have assessed the prevalence, risk factors, sociodemographics and genetics of PD in Australia. Similarly, details about disease onset, symptoms and progression and other medical comorbidities have not been collected and studied at a large-scale in a nation-wide sample. Long-running studies, such as the Griffith University Queensland Parkinson’s Project, have made significant contributions over the past 20 years in describing risk factors and mechanisms underlying PD’s pathological development and its disease progression [28–30]. Despite continued global scientific efforts, many questions remain around early and accurate diagnosis, differentiation, prognostication, and better traditional management methods and new treatment efforts such as neuroprotection and disease modification. With an aging population, the number of people with PD in Australia is set to increase dramatically. Thus, it is crucial to generate reliable evidence about the epidemiology and genetic aetiology of PD to inform policy and clinical practice. Ultimately, a more extensive representation of diverse Australian participants in worldwide PD studies may also lead to discovering novel therapeutic targets and developing new therapies and interventions to prevent, stop, or modify PD’s clinical course in Australia and the rest of the world.

Methodology

Here we describe the design of the Australian Parkinson’s Genetics study and baseline characteristics of the first wave of participants, including data collection methods, sociodemographic variables, environmental and lifestyle exposures, and self-reported history of medical conditions. Participants in the present study were Australian residents diagnosed with PD. The pilot project was initially conceived by researchers at the QIMR Berghofer Medical Research Institute (QIMRB) and approved by QIMRB’s Human Research Ethics Committee, with all participants providing informed consent for participation in the study and DNA genotyping.

Data collection

The online instruments consisted of several sections, covering sociodemographic, clinical, occupational, lifestyle and environmental factors, with a schematic of the APGS and questionnaire content shown in Figure 1. As part of the informed consent process, all participants agreed to be recontacted for future related studies, understanding that their participation in future studies is voluntary. The second wave of data collection is planned for the first half of 2021. It will include questions assessing heterogeneity in PD onset and motor and non-motor disability, including the following instruments: ∼80% of items in the Movement Disorder Society United Parkinson’s Disease Rating Scale (MDS-UPDRS) [32]; a short scale for the assessment of motor impairments and disability in Parkinson’s disease (The SPES/SCOPA); the Apathy Screening Tool; Geriatric Anxiety Inventory [32,33]; Geriatric Depression Scale (GDS); Assessment of Psychiatric Complications in Parkinson’s disease (The SCOPA-PC) [34]; and the SCOPA-sleep and PDSS scales [35] to identify sleep disorders in PD.

• Download figure
• Open in new tab

Figure 1. Schematic of the APGS and questionnaire content

Note: APGS, Australian Parkinson’s Disease Study; PBS, Pharmaceutical Benefits Scheme medication prescription database; PD, Parkinson’s disease; COPD, chronic obstructive pulmonary disease.

Results

We recruited 1,532 participants (average age = 64 years; SD = 6 years; range 40 – 88 years) for the Australian Genetics of Parkinson’s Disease Study carried out at QIMR Berghofer. Sociodemographic data were collected via web-based or paper questionnaires, with most participants (93%; N = 1,424) responding via the online questionnaire. Of our sample, 65% (N = 995) were males, with the sample mean self-reported BMI of 28 kg/m2 (SD = 5 kg/m2; range 17 – 55 kg/m2).

Most participants report being diagnosed with PD by a neurologist (83%; N = 1,260), having children (87%; N = 1,338), being married or in a de facto relationship (81%; N = 1,245) and are of European ancestry (92%; N = 1,397). Nearly 60% (N = 903) have a post-high school qualification and 15% (N = 228) speak more than one language. Tremor was the most common first symptom of PD reported in 788 respondents (54% of the sample group). The next most commonly reported symptoms were bradykinesia and muscle rigidity (20%, N = 291), followed by gait disorder (10%; N = 151), with an average age at onset of the first PD symptom of 57 years (SD = 8 years; range 27 – 86 years). The frequency of self-reported first symptom of PD in participants is presented in Figure 2.

• Download figure
• Open in new tab

Figure 2 Frequency of self-reported first symptom of PD in participants

Note: ‘Other’ symptoms included numbness, falls, olfactory dysfunction, small handwriting, loss of taste, slurred speech.

For 1,296 participants (85%), PD symptoms started on one side of the body, and more than half (44%) experienced the symptoms on the right side of the body. A large number of respondents (94%; N = 1,424) were currently on an anti-PD medication, 42% (N = 631) have experienced PD-related falls, and 12% (N = 177) reported having had a brain surgery for PD. The frequencies and percentage of all self-reported social, demographic and PD-related characteristics are outlined in Table 3.

Occupational and environmental risk factors of PD

Previously reported occupational (e.g., welding, metal melting, agriculture, petrochemistry) and environmental risk factors associated with PD were examined in this cohort and included exposure to pesticides or herbicides, head injury, well water drinking, working in high-risk occupations, living on a farm for over a year, and having metal poisoning or brain infection at any point across the life course. Approximately one-third of the sample (34%) reported being exposed to pesticides or herbicides at some point in their lives. Of those exposed to pesticides/herbicides, 390 were male, and 127 were female, with most of these cases (82%) reporting pesticide/herbicide exposure before 37 years of age.

Two hundred and forty-four participants (16% of the sample) had experienced head trauma, and the average age of head injury was 26 years (SD = 18 years; range 2 – 82 years). Of those with a previous head injury, 165 (67%) reported traumatic head injury with loss of consciousness. There was a significant positive association between the age of traumatic head injury and the age at onset of the first symptom of PD (Pearson correlation coefficient r = 0.3, p < 0.001) (Figure 3).

• Download figure
• Open in new tab

Figure 3

Relationship between the age of traumatic head injury and age at onset of the first symptom of Parkinson’s disease in participants

Eighty-two participants (5%) reported having frequently consumed water from a well for 19 years on average (SD = 12 years; range 2 – 50 years). A third of the sample (33%; N = 504) disclosed having worked in a high-risk occupation throughout their life, including welding, metal melting, galvanisation, milling, petrochemistry, agriculture, and wood processing, textile or industrial painting. Of these participants, 42% of respondents (N = 211) reported exposure to more than one occupational risk factor. Approximately 24% of the cohort (N = 360) worked or lived on a farm for more than a year, 1% (N = 22) acquired metal poisoning and 2% (N = 31) encephalitis (brain infection). The occupational and environmental risk factors of PD, summarised by sex, are shown in Table 4.

View this table:

• View inline
• View popup

Table 4

Occupational and environmental risk factors

Discussion

The present study describes sample characteristics of 1,532 Australians with PD recruited for the Australian Parkinson’s Genetics Study to unravel environmental and genetic associations with PD, along with PD heterogeneity, anti-PD medication response and adverse drug reactions.

Parkinson’s disease is a multifactorial disorder, and the estimated incidence of the disease varies with gender, age, and race or ethnicity [36,37]. We observed a higher prevalence of male participants than female (65% of males versus 35% of females), in line with most previous PD studies in various populations worldwide that found a significantly higher incidence rate of PD in males [36–38]. The causes of higher male-to-female ratios in PD are unknown, and it is still unclear whether male sex is an independent risk factor for PD. Estrogens are believed to be neuroprotective in females [39]. Nonetheless, whether males could also be at greater risk for developing PD due to higher exposure to environmental or occupational risk factors, future studies leveraging the APGS will be aimed at filling out these gaps in knowledge and pinpointing the role of sex hormones in PD.

The present study is the first to employ an assisted mailout approach to recruit PD participants from all Australian states. We found that individuals of European descent (92% of the sample group) were the most prevalent in the APGS, with a lower proportion of participants from Asian background (4%), Indigenous Australians and Torres Strait Islanders (1%), Africans (0.1%), Pacific Islanders (0.6%), Hispanics (0.3%), and in individuals of mixed ancestry (5%). We are unable to estimate differences in PD prevalence across ethnicities, given the lack of unaffected controls. Previous Australian epidemiological studies have reported PD prevalence rates between 66 and 415 per 100,000 Australians [40–42]. Similarly, worldwide PD prevalence has been consistently reported between 60 and 335 per 100,000 individuals, with a broad spectrum of ethnic backgrounds identified. For instance, the Israel population, Native Americans and Alaska Natives, have the highest prevalence (335/100 000 for Jewish Israeli and 355/100 000 for Native Americans and Alaska Natives) [43,44]. At the same time, Asian and African communities report the lowest prevalence rates [45–47]. The significantly increased prevalence of PD among distinct ethnic groups is partly attributable to a higher occurrence of PD-linked mutations in these populations (e.g., LRRK2 G2019S and GBA in Ashkenazi Jews) [48,49]. However, other factors such as variation in age groups surveyed, sampling methods, and diagnostic and screening criteria cannot be ruled out.

Parkinson’s disease is rare before the age of 50, and most patients present with symptoms in the late fifties [1]. Therefore, aging remains the primary risk factor for developing idiopathic PD [50–52], with the incidence of new cases increasing up to 10-fold between 60 and 90 years of age [36,53,54]. In our study, the mean age of onset for PD symptoms was 56 years, suggesting that self-selected PD participants may be among the younger age group, which tends to be more technology-savvy and motivated to participate in research. A possible explanation is that However, aging alone is insufficient to cause PD, and a complex relationship between aging and genetic and environmental factors prompts the disease onset [55]. Aging-associated impairments [56,57] and degeneration of dopaminergic neurons [58] may explain the steep rise in PD prevalence with age in cellular pathways.

Previous research suggests that exposure to toxic environmental agents (e.g., pesticides [10,59]), work-related iron or manganese exposure [60], farming or agricultural work [61] and traumatic head injury [62–64] are associated with increased risk of PD. However, the strength of these associations varies across studies and remains unclear. In light of these uncertainties, we investigated environmental and occupational exposures to assess their potential association with PD. Our results suggest that pesticide or herbicide exposure, working in known high-risk occupations, and working or living on a farm for over a year and suffering a head trauma are prevalent risk factors in the APGS. Interestingly, of those with traumatic brain injury, two-thirds reported having lost consciousness following head trauma.

Previous studies have shown that a traumatic brain injury with loss of consciousness early in life is associated with late-life neurodegenerative conditions, accumulation of Lewy bodies, PD progression, and increased PD risk [65]. However, the pathogenesis of brain injury and its link with neurodegenerative disorders has not been fully elucidated. When exploring the relationship between head trauma and the onset of PD, we identified a significant positive association between the age of head injury and the age at onset of PD symptoms. Participants who had a head injury early in life also reported an earlier age at which the first PD symptoms were manifested. However, only a small percentage of the cohort reported a lifetime traumatic head injury. Thus, our results are aligned with the hypothesis in which traumatic brain injury may initiate or exacerbate PD, perhaps due to persistent inflammation, metabolic dysfunction and abnormal protein aggregation [66].

Lifestyle may affect PD susceptibility. For instance, alcohol [14,67,68], smoking [69,70] and caffeine [71,72] are negatively correlated with PD risk. Previous studies have found that alcohol users have a lower PD risk than non-alcohol users, and those who drink more are less susceptible to PD than those who drink less [68]. Excessive alcohol consumption has been found to reverse this protective effect, increasing PD susceptibility independent of gender [73]. We observed a positive association between alcohol use and PD age of onset in the AGPD sample whereby participants with PD who had more alcoholic drinks consumed per week reported a later age of onset of PD compared to those who consumed less alcoholic drinks weekly. This interim observation agrees with previous findings and may imply that alcohol has a protective effect and delays the onset of PD. However, this needs to be explored further due to the possibility of ascertainment bias (e.g., alcohol consumption has negative effects on health and increases risk of mortality risk).

An inverse association has also been reported between smoking and PD in several longitudinal studies. A lower PD risk was observed among current and past smokers compared with never smokers [69,74]. Notably, smoking duration and intensity have been inversely related to PD risk, with PD susceptibility decreasing up to 70% when the duration of smoking in years increased [69]. In contrast, we observed an earlier age of symptoms onset in those who smoked more cigarettes/cigars/pipes per day than those who smoked fewer. This should be interpreted with caution, given the small sample size. Also, a recent Mendelian randomisation study by us [75] indicated that the continuation of the smoking habit rather than smoking heaviness (i.e., numbers of cigarettes smoked per day) is what may exert the protective effect of smoking over PD risk.

Similarly, prospective studies assessing lifetime coffee and tea consumption and PD highlight a negative correlation between caffeine in coffee or tea and PD risk [76], and the effect is more pronounced among men than women who regularly drink coffee or tea [71,77,78]. Importantly, there is substantial between-study heterogeneity across reported effect estimates. Our results on the correlation between caffeinated tea consumption and age of onset of PD are similar to those previously reported by others [79], with regular tea consumers reporting a later age of symptom onset than non-habitual tea consumers. The precise mechanisms underlying this relationship between lifestyle variables and PD susceptibility are poorly understood.

While there is strong evidence for the contribution of environmental factors in PD risk, it remains unclear why some individuals are more susceptible to PD. To advance our understanding of individual variability in vulnerability to environmental and lifestyle exposures, APGS will explore gene-environment interactions to detect potential genetic modifiers of PD susceptibility.

Comorbid medical conditions in PD patients could result from the underlying neurodegenerative processes occurring in the mesolimbic pathways, locus coeruleus and raphe nuclei, or could be due to changes in the dopaminergic, noradrenergic and serotonergic systems [80–82]. These prominent non-motor symptoms significantly reduce the quality of life of PD patients and lead to poor medication adherence and deterioration in their physical and mental status. Thus, it is urgently needed to identify disabling medical conditions co-occurring with PD to improve health outcomes and clinical management of PD patients in Australia. Consistent with previous findings we report high rates of comorbidities including constipation [83,84], depression [85,86], anxiety disorder [87], melanoma [88,89] and diabetes [90]. Although the prevalence estimates of common comorbidities in our cohort are higher than in the general population [91–94], our results support the body of evidence that these particular conditions are substantially more common among people with PD and thus may share a common aetiology.

In summary, we report the baseline characteristics of the APGS pilot cohort. The APGS aims to characterise and improve our understanding of the sociodemographic, genetic, and environmental basis of PD susceptibility, symptoms and progression in Australia. We used an innovative and highly-efficient recruitment approach through assisted mailouts, establishing feasibility and laying the groundwork for expanding and extending the study’s scale and reach in the future. With a 9% response rate to our mailout approach, the results of this study will provide an unprecedented opportunity for generating robust evidence on the epidemiology and genetic aetiology of PD to inform policy and clinical practice in the country. Ultimately, a more extensive representation of diverse Australian participants in worldwide PD studies may lead to a better understanding of the causes of PD and help in the discovery and validation of novel therapeutic targets and the development of new therapies and interventions to prevent, stop or modify the clinical course of PD in Australia and the rest of the world.

Twitter

@QIMRBerghofer, @mrenteria_

Author’s contributions

MER designed the APGS study with input from GDM, JG, PM, PCP, PL, DZL, SEM, NGM and CRS. AM, AIC, BLM, LMGM revised and tested the questionnaire and provided intellectual input into the content. RP coordinated the project and sample collection with help from SC and MF. SV cleaned and analysed the data for this cohort profile manuscript. SV and MER drafted the manuscript. All coauthors revised the article for intellectual content. All authors have read and approved the final version of the manuscript.

Funding

The APGS mailout was primarily funded by National Health and Medical Research Council (NHMRC) and the Australian Research Council (ARC) through an NHMRC-ARC Dementia Research Development Fellowship award to MER (GNT1102821).

Competing interests

The authors declare no competing interests.

Patient consent for publication

Obtained.

Disclosure statement

CRS has collaborated with Pfizer, Opko, Proteome Sciences, Genzyme Inc; has consulted for Genzyme; has served as Advisor to the Michael J. Fox Foundation, NIH, Department of Defense; is on the Scientific Advisory Board of the American Parkinson Disease Association; has received funding from the NIH, the U.S. Department of Defense, the Harvard NeuroDiscovery Center, the Michael J. Fox Foundation, and American Parkinson Disease Association. XD has received funding from the NIH, the Michael J. Fox Foundation, and American Parkinson Disease Association.

Ethics approval

This study has been approved by the Human Research Ethics Committee of the QIMR Berghofer Medical Research Institute.

Data availability statement

Data is available upon reasonable request for research purposes, in anonymised form, to preserve participants’ identity. Inquiries from potential scientific collaborators can be directed to the corresponding author (Miguel.Renteria{at}qimrberghofer.edu.au).

Tables

Tables 1 to 6 can be found here: https://docs.google.com/document/d/1zI_EMPzNZuMnw_auXLR6sMZ9w_jRs-EwsqqNSJZKQPc/edit?usp=sharing

Figures

Figures 1 to 3 can be found here: https://docs.google.com/document/d/1pyzSTS5omsITXqvhqvf0zl11_lFAZ2AncELUNuaIKog/edit?usp=sharing